Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Ipamorelin
Also known as: IPA, NNC 26-0161
Ipamorelin is a selective growth hormone secretagogue pentapeptide that stimulates GH release from the pituitary without significantly affecting cortisol, prolactin, or ACTH levels. It is considered one of the mildest and most selective GHRPs available. Its favorable side-effect profile makes it popular for GH optimization protocols.
Risk Level
Low RiskDifficulty
Beginner| CAS Number | 170851-70-4 |
| Molecular Formula | C38H49N9O5 |
| Class | Peptide |
| Category | Well-Known Peptides |
Mechanism of Action
Ipamorelin acts as a selective agonist at the ghrelin/GHS-R1a receptor on pituitary somatotrophs, triggering calcium influx and GH vesicle exocytosis. Unlike GHRP-6 and GHRP-2, it does not significantly stimulate appetite or raise cortisol and prolactin, indicating high receptor selectivity. It works synergistically with GHRH analogs like CJC-1295 to amplify pulsatile GH release.
Dosing Research
Typical dosing is 100-300 mcg subcutaneously 2-3 times daily, often timed around meals and before sleep. It is frequently stacked with Mod GRF 1-29 at equal doses for synergistic GH release. Cycles generally run 8-16 weeks.
Side Effects & Risks
Side effects are generally mild and may include headache, lightheadedness, and injection site irritation. Water retention is less common compared to other GHRPs. Rare reports include transient numbness and mild fatigue.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.